CN112272666A - 用于治疗癌症的化合物 - Google Patents

用于治疗癌症的化合物 Download PDF

Info

Publication number
CN112272666A
CN112272666A CN201980037767.2A CN201980037767A CN112272666A CN 112272666 A CN112272666 A CN 112272666A CN 201980037767 A CN201980037767 A CN 201980037767A CN 112272666 A CN112272666 A CN 112272666A
Authority
CN
China
Prior art keywords
substituted
unsubstituted
compound
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980037767.2A
Other languages
English (en)
Chinese (zh)
Inventor
M·卢奇欧
K·麦卡锡
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Skihawk Therapy
Original Assignee
Skihawk Therapy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Skihawk Therapy filed Critical Skihawk Therapy
Publication of CN112272666A publication Critical patent/CN112272666A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/14—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201980037767.2A 2018-04-10 2019-04-10 用于治疗癌症的化合物 Pending CN112272666A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862655431P 2018-04-10 2018-04-10
US62/655,431 2018-04-10
PCT/US2019/026788 WO2019199972A1 (en) 2018-04-10 2019-04-10 Compounds for the treatment of cancer

Publications (1)

Publication Number Publication Date
CN112272666A true CN112272666A (zh) 2021-01-26

Family

ID=68164559

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980037767.2A Pending CN112272666A (zh) 2018-04-10 2019-04-10 用于治疗癌症的化合物

Country Status (6)

Country Link
US (1) US11530207B2 (https=)
EP (1) EP3781564B1 (https=)
JP (1) JP2021521200A (https=)
KR (1) KR20200142039A (https=)
CN (1) CN112272666A (https=)
WO (1) WO2019199972A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112662780A (zh) * 2021-01-29 2021-04-16 复旦大学附属中山医院 检测hnrnpm表达的试剂在制备诊断和/或预后判断肝癌中的应用及药物组合物

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019028440A1 (en) 2017-08-04 2019-02-07 Skyhawk Therapeutics, Inc. METHODS AND COMPOSITIONS FOR MODULATING SPLICING
CN113692402A (zh) * 2019-02-04 2021-11-23 斯基霍克疗法公司 用于调节剪接的方法和组合物
WO2020163248A1 (en) 2019-02-04 2020-08-13 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
CN114126613A (zh) * 2019-02-05 2022-03-01 斯基霍克疗法公司 用于调节剪接的方法和组合物
CN113677342A (zh) * 2019-02-05 2021-11-19 斯基霍克疗法公司 用于调节剪接的方法和组合物
KR20210134657A (ko) * 2019-02-05 2021-11-10 스카이호크 테라퓨틱스, 인코포레이티드 스플라이싱을 조절하는 방법 및 조성물
EP3920915A4 (en) 2019-02-05 2022-10-05 Skyhawk Therapeutics, Inc. METHODS AND COMPOSITIONS FOR MODULATING SPLICE
WO2020163544A1 (en) 2019-02-06 2020-08-13 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
CN113661162A (zh) 2019-02-06 2021-11-16 斯基霍克疗法公司 用于调节剪接的方法和组合物
AR119731A1 (es) 2019-05-17 2022-01-05 Novartis Ag Inhibidores del inflamasoma nlrp3
WO2021071983A1 (en) * 2019-10-08 2021-04-15 Skyhawk Therapeutics, Inc. Compounds for modulating splicing
WO2021071984A1 (en) * 2019-10-08 2021-04-15 Skyhawk Therapeutics, Inc. Compounds for modulating splicing
WO2021071981A1 (en) * 2019-10-08 2021-04-15 Skyhawk Therapeutics, Inc. Compounds for modulating splicing
CA3169697A1 (en) 2020-02-28 2021-09-02 Dominic Reynolds Thiophenyl derivatives useful for modulating nucleic acid splicing
MX2022010634A (es) 2020-02-28 2023-01-19 Remix Therapeutics Inc Derivados de piridazina para modular el empalme de acidos nucleicos.
WO2021174167A1 (en) 2020-02-28 2021-09-02 Remix Therapeutics Inc. Compounds and methods for modulating splicing
JP7736700B2 (ja) 2020-02-28 2025-09-09 リミックス セラピューティクス インコーポレイテッド 複素環アミド及びスプライシングを調節するためのその使用
KR20230005210A (ko) 2020-04-08 2023-01-09 레믹스 테라퓨틱스 인크. 스플라이싱을 조절하기 위한 화합물 및 방법
JP2023520916A (ja) 2020-04-08 2023-05-22 リミックス セラピューティクス インコーポレイテッド スプライシングを調整するための化合物及び方法
EP4178963A1 (en) 2020-07-02 2023-05-17 Remix Therapeutics Inc. 5-[5-(piperidin-4-yl)thieno[3,2-c]pyrazol-2-yl]indazole derivatives and related compounds as modulators for splicing nucleic acids and for the treatment of proliferative diseases
EP4175956A1 (en) 2020-07-02 2023-05-10 Remix Therapeutics Inc. 2-(indazol-5-yl)-6-(piperidin-4-yl)-1,7-naphthyridine derivatives and related compounds as modulators for splicing nucleic acids and for the treatment of proliferative diseases
CN116940578A (zh) * 2020-07-02 2023-10-24 雷密克斯医疗公司 5-[5-(哌啶-4-基)噻吩并[3,2-c]吡唑-2-基]吲唑衍生物和相关化合物作为调节剂用于剪接核酸和治疗增殖性疾病
EP4192454B1 (en) * 2020-08-05 2026-04-22 Skyhawk Therapeutics, Inc. Azabicyclo-amino-triazine compounds for modulating splicing for the treatment of neurological diseases
WO2022060951A1 (en) * 2020-09-16 2022-03-24 Skyhawk Therapeutics, Inc. Compositions for modulating splicing
GB2603454A (en) * 2020-12-09 2022-08-10 Ucl Business Ltd Novel therapeutics for the treatment of neurodegenerative disorders
US20240400584A1 (en) 2021-08-30 2024-12-05 Remix Therapeutics Inc. Compounds and methods for modulating splicing
US20240368163A1 (en) 2021-08-30 2024-11-07 Remix Therapeutics Inc. Compounds and methods for modulating splicing
WO2023034836A1 (en) 2021-08-30 2023-03-09 Remix Therapeutics Inc. Compounds and methods for modulating splicing
WO2023034812A1 (en) 2021-08-30 2023-03-09 Remix Therapeutics Inc. Compounds and methods for modulating splicing
IL311132A (en) 2021-08-30 2024-04-01 Remix Therapeutics Inc Splicing Modulation Compounds and Methods
CA3233973A1 (en) 2021-10-13 2023-04-20 Dominic Reynolds Compounds and methods for modulating nucleic acid splicing
WO2023064879A1 (en) 2021-10-13 2023-04-20 Remix Therapeutics Inc. Compounds and methods for modulating nucleic acid splicing
US20250109140A1 (en) 2022-01-05 2025-04-03 Remix Theraputics Inc. 5-[5-(piperidin-4-yl)thieno[3,2-c]pyrazol-2-yl]indazole derivatives and related compounds as modulators for splicing nucleic acids and for the treatment of proliferative diseases
US20250326748A1 (en) 2022-01-05 2025-10-23 Remix Therapeutics Inc. Compounds and methods for modulating splicing
WO2023133217A1 (en) 2022-01-05 2023-07-13 Remix Therapeutics Inc. 2-(indazol-5-yl)-6-(piperidin-4-yl)-1,7-naphthyridine derivatives and related compounds as modulators for splicing nucleic acids and for the treatment of proliferative diseases
UY40374A (es) 2022-08-03 2024-02-15 Novartis Ag Inhibidores de inflamasoma nlrp3

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5128118A (en) * 1990-08-09 1992-07-07 Research Triangle Institute Cocaine receptor binding ligands
US20040229864A1 (en) * 2003-05-15 2004-11-18 Sylvie Bourrain Sulfone derivatives as 5-HT7 receptor ligands
US20070207985A1 (en) * 2006-03-01 2007-09-06 Bristol-Myers Squibb Company Triazine 11-beta hydroxysteroid dehydrogenase type 1 inhibitors
CN101035792A (zh) * 2004-10-20 2007-09-12 神经研究公司 新颖的二氮杂双环芳基衍生物和它们的医药用途
US20080275048A1 (en) * 2003-09-19 2008-11-06 Abbott Laboratories Substituted Diazabicycloalkane Derivates
CN102046595A (zh) * 2008-03-27 2011-05-04 格吕伦塔尔有限公司 取代的4-氨基环己烷衍生物
CN104583196A (zh) * 2012-08-13 2015-04-29 诺华股份有限公司 1,4-二取代的哒嗪类似物以及治疗与smn缺乏相关的病症的方法
CN105392790A (zh) * 2013-08-19 2016-03-09 豪夫迈·罗氏有限公司 筛选方法
EP3053577A1 (en) * 2015-02-09 2016-08-10 F. Hoffmann-La Roche AG Compounds for the treatment of cancer
WO2016196386A1 (en) * 2015-05-30 2016-12-08 Ptc Therapeutics, Inc. Methods for modulating rna splicing
WO2017100726A1 (en) * 2015-12-10 2017-06-15 Ptc Therapeutics, Inc. Methods for treatng huntington's disease
CN107428729A (zh) * 2015-02-09 2017-12-01 豪夫迈·罗氏有限公司 用于治疗癌症的化合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR901464A (fr) 1943-01-23 1945-07-27 Boehringer & Soehne Gmbh Procédé d'obtention de vanilline
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
US7189737B2 (en) * 1991-08-09 2007-03-13 Research Triangle Institute Cocaine receptor binding ligands
FR2926297B1 (fr) * 2008-01-10 2013-03-08 Centre Nat Rech Scient Molecules chimiques inhibitrices du mecanisme d'epissage pour traiter des maladies resultant d'anomalies d'epissage.
WO2019028440A1 (en) 2017-08-04 2019-02-07 Skyhawk Therapeutics, Inc. METHODS AND COMPOSITIONS FOR MODULATING SPLICING
KR20200057071A (ko) 2017-09-25 2020-05-25 스카이호크 테라퓨틱스, 인코포레이티드 스플라이싱 조절제의 스크리닝 및 확인을 위한 방법 및 조성물

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5128118A (en) * 1990-08-09 1992-07-07 Research Triangle Institute Cocaine receptor binding ligands
US20040229864A1 (en) * 2003-05-15 2004-11-18 Sylvie Bourrain Sulfone derivatives as 5-HT7 receptor ligands
US20080275048A1 (en) * 2003-09-19 2008-11-06 Abbott Laboratories Substituted Diazabicycloalkane Derivates
CN101035792A (zh) * 2004-10-20 2007-09-12 神经研究公司 新颖的二氮杂双环芳基衍生物和它们的医药用途
US20070207985A1 (en) * 2006-03-01 2007-09-06 Bristol-Myers Squibb Company Triazine 11-beta hydroxysteroid dehydrogenase type 1 inhibitors
CN102046595A (zh) * 2008-03-27 2011-05-04 格吕伦塔尔有限公司 取代的4-氨基环己烷衍生物
CN104583196A (zh) * 2012-08-13 2015-04-29 诺华股份有限公司 1,4-二取代的哒嗪类似物以及治疗与smn缺乏相关的病症的方法
CN105392790A (zh) * 2013-08-19 2016-03-09 豪夫迈·罗氏有限公司 筛选方法
EP3053577A1 (en) * 2015-02-09 2016-08-10 F. Hoffmann-La Roche AG Compounds for the treatment of cancer
CN107428729A (zh) * 2015-02-09 2017-12-01 豪夫迈·罗氏有限公司 用于治疗癌症的化合物
WO2016196386A1 (en) * 2015-05-30 2016-12-08 Ptc Therapeutics, Inc. Methods for modulating rna splicing
WO2017100726A1 (en) * 2015-12-10 2017-06-15 Ptc Therapeutics, Inc. Methods for treatng huntington's disease

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DEEPAK KUMAR等: "Selectivity in Small Molecule Splicing Modulation", 《ACS CHEM. BIOL.》 *
LIYING FAN等: "Sudemycins, Novel Small Molecule Analogues of FR901464, Induce Alternative Gene Splicing", 《ACS CHEM. BIOL.》 *
MICHAEL SEILER等: "H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers", 《NATURE MEDICINE》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112662780A (zh) * 2021-01-29 2021-04-16 复旦大学附属中山医院 检测hnrnpm表达的试剂在制备诊断和/或预后判断肝癌中的应用及药物组合物

Also Published As

Publication number Publication date
JP2021521200A (ja) 2021-08-26
US20210292316A1 (en) 2021-09-23
US11530207B2 (en) 2022-12-20
KR20200142039A (ko) 2020-12-21
EP3781564A1 (en) 2021-02-24
EP3781564B1 (en) 2023-08-23
EP3781564C0 (en) 2023-08-23
WO2019199972A1 (en) 2019-10-17

Similar Documents

Publication Publication Date Title
CN112272666A (zh) 用于治疗癌症的化合物
JP7135026B2 (ja) スプライシングをモジュレートする方法および組成物
JP7682096B2 (ja) スプライシングを調節するための方法および組成物
US11845744B2 (en) Methods and compositions for modulating splicing
JP7603595B2 (ja) スプライシングを調節するための方法および組成物
JP7551629B2 (ja) スプライシングを調節するための方法および組成物
JP7603594B2 (ja) スプライシングを調節するための方法および組成物
JP2022525417A (ja) 異常スプライシングを修正するための組成物および方法
TW201341386A (zh) 唑並［１，５－ａ］嘧啶基化合物、包含其之組成物及其使用方法
WO2021071984A1 (en) Compounds for modulating splicing
CN114269922A (zh) 用于调节剪接的方法
CN113692402A (zh) 用于调节剪接的方法和组合物
WO2021071981A1 (en) Compounds for modulating splicing
JP2024153885A (ja) 新規なピラゾール誘導体
CN113660936A (zh) 用于调节剪接的方法和组合物
CN111727191A (zh) 取代的氮杂环丁烷二氢噻吩并吡啶类化合物及其作为磷酸二酯酶抑制剂的用途
WO2021071982A1 (en) Compounds for modulating splicing
WO2021071983A1 (en) Compounds for modulating splicing
WO2025113705A1 (zh) N-取代酰胺类衍生物抑制剂、其制备方法和应用
CN120829430A (zh) 三稠环类衍生物抑制剂、其制备方法和应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210126